A Phase Ib Trial of Patients With Advanced Hematologic Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation With Either Orca-T, a T-cell-Depleted Graft With Additional Infusion of Conventional T Cells and Regulatory T Cells, or Standard-of-Care Allogeneic Graft
Latest Information Update: 09 May 2025
At a glance
- Drugs Orca-T (Primary)
- Indications Acute biphenotypic leukaemia; Acute myeloid leukaemia; Blastic plasmacytoid dendritic cell neoplasm; Myelodysplastic syndromes; Myelofibrosis; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Therapeutic Use
- Sponsors Orca Bio
Most Recent Events
- 02 May 2025 Planned End Date changed from 1 Jul 2026 to 1 Apr 2027.
- 02 May 2025 Planned primary completion date changed from 1 Jul 2024 to 30 Apr 2025.
- 10 Feb 2025 According to an Orca Bio media release, data from the study will be presented at the 51st Annual Meeting of the EBMT held March 30-April 2, 2025 in Florence, Italy.